Updates to COVID-19 Clinical Insights Document
4/7/2020

- New sections
  - Diagnosis of SARS-CoV-2 Infection
  - COVID-19 Liver Disease/Transplant Registries
- New tables
  - Diagnostic Methods for SARS-CoV-2 Detection
  - Investigational Treatments for COVID-19
- New figures
  - Approach to the Patient with COVID-19 and Elevated Serum Liver Biochemistries
  - Approach to Liver Transplant Organ Offers
  - Approach to the Liver Transplant Recipient with COVID-19
- Expanded “What We Know” sections
- Added virology of SARS-CoV-2
- Added liver histology in COVID-19
- Expanded COVID-19 symptoms for screening: sore throat, diarrhea, new loss of sense of taste or smell
- Expanded complications of COVID-19 complications when evaluating patients with elevated liver tests: myositis, cytokine release syndrome, ischemia/hypotension, DILI
- Clarified recommendations for treatment of patients with liver disease
  - Recommend continue treatment for hepatitis B or C
  - Consider delaying initiation of hepatitis C treatment
  - Removed specific prednisone 10 mg recommendation to avoid confusion when tapering high-dose prednisone in patients with COVID-19
  - Recommend initiating immunosuppressive therapy in patients with liver disease with or without COVID-19 who have strong indications for treatment (e.g., autoimmune hepatitis, graft rejection)
- Clarified recommendations for monitoring patients with HCC and surveillance of patients at risk for HCC
- Expanded section on Medication Management of Patients with COVID-19 to include new information about investigational agents
- Revised PPE recommendations for endoscopic procedures to include N95 masks